Ph+ acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

Blood

Volumn 99, Issue 5, 2002, Pages 1860-1862

  Hofmann, Wolf K ^a,b,c   Jones, Letetia C ^a,b,c   Lemp, Nathan A ^a,b,c   De Vos, Sven ^a,b,c   Gschaidmeier, Harald ^a,b,c   Hoelzer, Dieter ^a,b,c   Ottmann, Oliver G ^a,b,c   Phillip Koeffler, H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Novartis Pharma AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BINDING SITE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0036493544     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.5.1860     Document Type: Article

References (21)

1. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
2. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
3. A phase II study to determine the safety and antileukemic effect of STI571 in adult patients with Philadelphia chromosome positive acute leukemias
4. Development of acute lymphoblastic leukemia and myeloproliferative disorder in transgenic mice expressing p210bcr/abl: A novel transgenic model for human Ph1-positive leukemias
5. Reversibility of acute B-cell leukaemia induced by BCR-ABL1
6. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
7. Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia
8. Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase
9. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
10. An improvement of the single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
11. Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias
12. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
13. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
14. Another possible mechanism of resistance to STI571
15. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification
16. Isolation and characterization of Caenorhabditis elegans DNA sequences homologous to the v-abl oncogene
17. Control of photoreceptor cell fate by the sevenless protein requires a functional tyrosine kinase domain
18. Mammalian AMP-activated protein kinase subfamily
19. Roots of clinical resistance to STI-571 cancer therapy
20. Roots of clinical resistance to STI-571 cancer therapy
21. Response to "Roots of clinical resistance to STI-571 cancer therapy"